my point had been made previously, I am just re-pointing to the concerns
accept pi88 will have similar label warnings, but some key differences
worth a read of the liver phii sae
http://www.progen-pharma.com/prs/progen_...
not much really related to treatment at 160 mg, can't quite work it out but 2 sae related to treatment at 160mg (?) out of 56, and only 4 all up for 160mg+250mg out of 110, not sure about control
and melanoma sae on 250 mg, 5 out of 44 with at least some not likely related to treatment, not sure about expected with no treatment
http://www.progen.com.au/prs/Clinical%20...
Grade 3/4 adverse events were 38% for Nexavar vs. 28% for placebo
see below for not insignificant rates that nexavar patients hair falls out, they get itchy, diarrhea, rash, sick, bleeding, blood pressure
and for 2.5% of them, the old cardiac ischemia/infarction was 2.9% for Nexavar vs. 0.4% for placebo
i think there is a point of difference
given similar activity, which would you rather be on
- Forums
- ASX - By Stock
- PGL
- broker report says sell with valuation 1.50
broker report says sell with valuation 1.50, page-10
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PGL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online